{
    "clinical_study": {
        "@rank": "16735", 
        "arm_group": [
            {
                "arm_group_label": "PC-1005", 
                "arm_group_type": "Experimental", 
                "description": "4.00 g dosed once daily for 3 days (safety run-in)\n4.00 g dosed once daily for 14 days (main study)"
            }, 
            {
                "arm_group_label": "HEC gel", 
                "arm_group_type": "Placebo Comparator", 
                "description": "4.00 g dosed once daily for 14 days (main study only)"
            }
        ], 
        "brief_summary": {
            "textblock": "This Phase 1 clinical trial will evaluate MIV-150, a third generation non-nucleoside reverse\n      transcriptase inhibitor, co-formulated with a potentially potent agent, zinc acetate for the\n      prevention of HIV infection in women.  This is the first in-human of PC-1005 (MIV-150/zinc\n      acetate in a carrageenan gel), the first study in which females will be exposed to MIV-150,\n      the first time MIV-150 will be administered topically, and the first time MIV-150 will be\n      administered intravaginally."
        }, 
        "brief_title": "Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV", 
        "detailed_description": {
            "textblock": "This study will begin with a safety run-in, which is an open label, single-arm safety run-in\n      with 5 women receiving PC-1005 once daily for 3 consecutive days.  Safety and\n      pharmacokinetics will take place after each dose.  the participants from the run-in will not\n      be eligible for the main study.\n\n      The main study participants will be randomized 4:1 to the study gels: 24 randomized to\n      PC-1005 (active) and 6 randomized to HEC gel (placebo).  The study product will be applied\n      vaginally once daily for 14 days with clinical and laboratory assessments at baseline\n      (enrollment) and after the 1st, 2nd, 8th, 9th, and 14th doses, and a safety follow-up visit\n      7 days after the 14th dose.\n\n      Participants in the run-in and main study will be requested to be sexually abstinent\n      starting immediately after the Screening Visit until study exit."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women between 18 and 49 years of age, inclusive\n\n          -  Willing and able to provide written informed consent\n\n          -  Healthy, based on medical history, vital signs, physical examination, urinalysis,\n             laboratory evaluations for genital infections and laboratory evaluations for\n             hematology, liver and renal function\n\n          -  HIV-negative as determined by HIV ELISA test at screening\n\n          -  Hepatitis B and C negative at screening\n\n          -  Rapid plasma reagin negative at screening\n\n          -  If HSV-2 positive, must be free from outbreaks for at least 6 months prior to\n             screening\n\n          -  In the absence of the use of exogenous hormone(s), have a self-reported regular\n             menstrual cycle, defined as having a minimum of 21 days and a maximum of 35 days\n             between menses\n\n          -  Normal Pap test at screening\n\n          -  Agrees to use one form of effective contraception for the duration of the trial\n\n          -  Willing to abstain from sexual intercourse/activity including receptive vaginal,\n             oral, digital, and anal intercourse, and the use of any vaginal products including\n             tampons, male and female condoms, contraceptive sponges, diaphragms, cervical caps,\n             douches, lubricants, and vibrators/dildos starting from the Screening Visit through\n             Study Exit\n\n          -  Agrees to not participate in any other clinical research trial for the duration of\n             this trial\n\n        Exclusion Criteria:\n\n          -  History of or known sensitivity/allergy to any component of either study product\n\n          -  Currently pregnant or breast-feeding, or within 3 months of last pregnancy outcome\n\n          -  Participation in any other clinical research trial involving investigational or\n             marketed products currently or within two months of participation prior to screening,\n             including any trial of a spermicide, microbicide and/or drug\n\n          -  Diagnosed with or treated for any STI (other than HSV) or pelvic inflammatory disease\n             in the last 3 months\n\n          -  Positive test for Neisseria gonorrhea, Chlamydia trachomatis, or Trichomonas\n             vaginalis\n\n          -  Symptomatic vulvovaginal candidiasis, bacterial vaginosis (BV), or urinary tract\n             infection (UTI) at screening\n\n          -  Deep epithelial findings such as abrasions, ulcerations, or lacerations, or vesicles\n             suspicious for STIs at screening\n\n          -  Presence of any other clinically significant abnormal physical finding on the vulva,\n             vaginal walls or cervix at screening\n\n          -  Any Grade 2, 3 or 4 hematology, chemistry or urinalysis laboratory abnormality at\n             screening according to the Division of AIDS (DAIDS) Table for Grading Adverse Events\n\n          -  Any serious acute, chronic (excluding HSV-2) or progressive disease (including any\n             known history of cancer, diabetes, cardiac disease, autoimmune disease, blood\n             dyscrasias, or Wilson's disease), or signs of cardiovascular disease, or renal\n             failure\n\n          -  History of hysterectomy or menopause\n\n          -  Use of excluded contraceptive methods including Nuvaring\u00ae, depo-medroxyprogesterone\n             acetate (DMPA; Depo-Provera\u00ae), condoms (male or female), contraceptive sponge,\n             diaphragm, cervical cap, IUD, IUS\n\n          -  History of gynecological surgery or procedure within past 2 months\n\n          -  History of uterine prolapse, undiagnosed vaginal bleeding or urethral obstruction\n             within the last 3 months\n\n          -  Known current drug abuse, including illicit drugs, or alcohol abuse\n\n          -  Any other condition(s) that, in the opinion of the Investigator, might interfere with\n             adherence to trial requirements or evaluation of the trial objectives\n\n          -  Unable to comply with study requirements, including but not limited to, attending all\n             study visits, using the gel as directed, observing abstinence throughout the study\n             and use of effective contraceptives"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "49 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033109", 
            "org_study_id": "Population Council #558"
        }, 
        "intervention": [
            {
                "arm_group_label": "PC-1005", 
                "description": "Intravaginal use", 
                "intervention_name": "PC-1005", 
                "intervention_type": "Drug", 
                "other_name": "MIV-150/zinc acetate in a carrageenan gel"
            }, 
            {
                "arm_group_label": "HEC gel", 
                "intervention_name": "HEC gel", 
                "intervention_type": "Drug", 
                "other_name": [
                    "hydroxyethylcellulose gel", 
                    "placebo gel"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 7, 2014", 
        "location": {
            "contact": {
                "last_name": "Craig J Hoesley, MD", 
                "phone": "205-934-3365"
            }, 
            "facility": {
                "address": {
                    "city": "Birmingham", 
                    "country": "United States", 
                    "state": "Alabama", 
                    "zip": "35294"
                }, 
                "name": "University of Alabama at Birmingham"
            }, 
            "investigator": {
                "last_name": "Craig J Hoesley, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Acceptability of PC-1005 Microbicide Gel Formulation in HIV-seronegative Women", 
        "other_outcome": [
            {
                "description": "Anti-HIV, anti-HSV, and anti-HPV activity in cervicovaginal lavages (CVL)\nImmune mediators in CVL", 
                "measure": "Exploratory: pharmacodynamics and immune mediators", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (baseline, both run-in and main); Day 14 (post-dose, main study only)"
            }, 
            {
                "description": "Use TearFlo\u00ae strips\nOne for MIV-150 and one for zinc", 
                "measure": "Exploratory: MIV-150 and zinc levels in vaginal fluid", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (baseline, both run-in and main); Day 14 (post-dose, main study only)"
            }, 
            {
                "description": "Additional cervical biopsy after the last dose", 
                "measure": "Exploratory: MIV-150 and zinc levels in cervical tissue biopsies (main study only)", 
                "safety_issue": "No", 
                "time_frame": "Day 14 (post-dose)"
            }, 
            {
                "description": "Sensitivity, specificity, negative predictive values and positive predictive values of the dye stain assay, using applicators inserted under direct observation as the positive controls\nCorrelation between self-reported adherence, pharmacokinetics, pharmacodynamics, number of returned applicators and dye stain assay", 
                "measure": "Exploratory: dye stain assay analysis", 
                "safety_issue": "No", 
                "time_frame": "Post-dose"
            }, 
            {
                "measure": "Exploratory: pharmacokinetics evaluation of zinc in resum", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2 and 3 (run-in) / Days 1, 8 and 14 (main study)"
            }
        ], 
        "overall_contact": {
            "last_name": "Barbara Friedland, MPH", 
            "phone": "212-339-0629"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Alabama at Birmingham", 
                "last_name": "Craig J Hoesley, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Population Council", 
                "last_name": "George W Creasy, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Population Council", 
                "last_name": "Barbara Friedland, MPH", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Number and percent of participants with treatment emergent adverse events and adverse events, and medical significance of adverse events and serious adverse events\nNumber, percent and medical significance of abnormalities in physical exams, pelvic exams, and biopsies once product has been administered\nNumber, percent and medical significance of abnormalities in clinical laboratory parameters once product has been administered", 
                "measure": "Safety: adverse events, serious adverse events, physical exams, and clinical laboratory parameters", 
                "safety_issue": "Yes", 
                "time_frame": "5 weeks for safety run-in study; 7 weeks for main study"
            }, 
            {
                "description": "Area under the plasma/serum concentration curve\nPeak plasma/serum concentration\nTrough plasma/serum concentration\nTime to peak plasma/serum concentration\nElimination half-life\nApparent clearance", 
                "measure": "Pharmacokinetics: evaluation of concentrations of MIV-150 in plasma", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2 and 3 (run-in) / Days 1, 8 and 14 (main study)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033109"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Questionnaire, self-report, and applicators returned empty", 
            "measure": "Assessment of acceptability and adherence of PC-1005 use in seronegative women (main study only)", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "source": "Population Council", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Population Council", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}